Education
About Us
Working with TipRanks
Follow Us
VolitionRX (VNRX)
:VNRX
VNRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.42 - $1.02
Previous CloseN/A
Volume29.92K
Average Volume (3M)235.81K
Market Cap
$49.37M
Enterprise Value$59.01M
Total Cash (Recent Filing)$725.00
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.71
Next Earnings
May 07, 2025EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.31
Shares Outstanding100,746,470
10 Day Avg. Volume438,822
30 Day Avg. Volume235,810
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)39.64
Price to Cash Flow (P/CF)-2.40
P/FCF Ratio0.00
Enterprise Value/Market Cap1.20
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit76.12
Enterprise Value/Ebitda-2.07
Forecast
1Y Price Target
$2.50Price Target Upside410.20% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
VolitionRX News
PremiumCompany Announcements
VolitionRX Files New Registration Statement with SEC
PremiumCompany Announcements
VolitionRx Ltd. Earnings Call Highlights Growth and Challenges
PremiumCompany Announcements
VolitionRx Limited Reports Strong 2024 Financial Results
---
Bulls Say, Bears Say
Bulls Say
Global ExpansionNu.Q Vet is now available for purchase in over 20 countries worldwide.
Licensing OpportunitiesManagement provided insight into growing licensing opportunities related to Nu.Q Cancer, which could be a simple and accessible routine blood test.
Bears Say
Competitive LandscapeVolition is advancing several active commercial discussions with significant players in the human diagnostic and liquid biopsy space for sepsis and oncology.
---
Ownership Overview
12.03% Insiders
1.28% Mutual Funds
0.14% Other Institutional Investors
85.93% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
VNRX FAQ
What was VolitionRX’s price range in the past 12 months?
VolitionRX lowest stock price was $0.42 and its highest was $1.02 in the past 12 months.
What is VolitionRX’s market cap?
VolitionRX’s market cap is $49.37M.
When is VolitionRX’s upcoming earnings report date?
VolitionRX’s upcoming earnings report date is May 07, 2025 which is in 15 days.
How were VolitionRX’s earnings last quarter?
VolitionRX released its earnings results on Mar 31, 2025. The company reported -$0.06 earnings per share for the quarter, missing the consensus estimate of -$0.044 by -$0.016.
Is VolitionRX overvalued?
According to Wall Street analysts VolitionRX’s price is currently Undervalued.
Does VolitionRX pay dividends?
VolitionRX does not currently pay dividends.
What is VolitionRX’s EPS estimate?
VolitionRX’s EPS estimate is -0.06.
How many shares outstanding does VolitionRX have?
VolitionRX has 100,746,470 shares outstanding.
What happened to VolitionRX’s price movement after its last earnings report?
VolitionRX reported an EPS of -$0.06 in its last earnings report, missing expectations of -$0.044. Following the earnings report the stock price went down -8.772%.
Which hedge fund is a major shareholder of VolitionRX?
Currently, no hedge funds are holding shares in VNRX
---
VolitionRX Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.50 (410.20% Upside)
$2.50 (410.20% Upside)
Blogger Sentiment
Bullish
VNRX Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $200.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 6.0%
Last 30 Days ▼ 6.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-17.50%
12-Months-Change
Fundamentals
Return on Equity
138.92%
Trailing 12-Months
Asset Growth
-66.37%
Trailing 12-Months
Company Description
VolitionRX
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company operates Nucleosomics a technology platform for blood test. VolitionRx Limited is based in Austin, Texas.
---
VNRX Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
VolitionRx showed significant progress in 2024 with strong revenue growth, successful cost reduction, and promising clinical advancements in both oncology and sepsis. However, challenges remain in achieving predictable revenue streams and cash flow management. The company's focus on securing multiple licensing deals in 2025 is critical to future success.Read More>---
VNRX Stock 12 Month Forecast
Average Price Target
$2.50
▲(410.20% Upside)
Technical Analysis
Enzo Biochem
―
BioNano Genomics
―
Burning Rock Biotech
―
Biodesix
―
bioAffinity Technologies, Inc.
―
Best Analysts Covering VNRX
1 Year
1 Year Success Rate
0/7 ratings generated profit
1 Year Average Return
-35.13%
reiterated a buy rating 11 months ago
Copying Ross Osborn's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -35.13% per trade.
---